Stay updated on Crizotinib in ALK, MET, ROS1 Alterations Clinical Trial
Sign up to get notified when there's something new on the Crizotinib in ALK, MET, ROS1 Alterations Clinical Trial page.

Latest updates to the Crizotinib in ALK, MET, ROS1 Alterations Clinical Trial page
- Check6 days agoChange DetectedThe record history now includes a new revision entry v3.4.3 and removes v3.4.2 from the history.SummaryDifference0.1%

- Check13 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check34 days agoChange DetectedAdded Revision: v3.4.2 to the study history. Removed the government funding lapse notice and deleted Revision: v3.4.1.SummaryDifference0.8%

- Check41 days agoChange DetectedAdded a government funding notice and updated the page revision to v3.4.1, replacing the previous v3.4.0 in the history.SummaryDifference0.8%

- Check48 days agoChange DetectedUI-related updates include Show glossary option, explanatory color-coding for record changes (green/red highlights) and related text, and a revision update from v3.3.4 to v3.4.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference1%

- Check62 days agoChange DetectedA new revision entry v3.3.4 was added and the previous revision v3.3.3 was removed.SummaryDifference0.1%

- Check84 days agoChange DetectedA new Revision: v3.3.3 entry was added to the history and references to HHS Vulnerability Disclosure and Revision: v3.3.2 were removed. This appears to be a routine maintenance update and does not alter the study record content.SummaryDifference0.2%

Stay in the know with updates to Crizotinib in ALK, MET, ROS1 Alterations Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Crizotinib in ALK, MET, ROS1 Alterations Clinical Trial page.